Overexpression of glutathione-S-transferase, MGSTII, confers resistance to busulfan and melphalan
For now, the most accurate statement is that both treatments produce approximately 20 to 23% weight loss in non-diabetic populations with obesity, and both are in a class far beyond anything that came before them
or features suggesting systemic illness or significant androgen excess
Market Expansion and Regulatory Evolution Regulatory bodies are becoming more aware that obesity is a long-term disease that needs medication treatment
Seek medical attention promptly if you experience symptoms that could suggest serious underlying conditions, including: Unexplained weight loss or persistent fatigue Jaundice (yellowing of skin or eyes), abdominal pain, or swelling Easy bruising or bleeding , or unusual skin rashes Night sweats , fever, or enlarged lymph nodes Reduced urine output , significant swelling in legs or ankles Persistent itching without obvious skin cause These symptoms may indicate liver disease, haematological disorders, or renal impairmentconditions that can elevate B12 and require specialist assessment